SEC Form S-8 POS filed by Freeline Therapeutics Holdings plc

$FRLN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $FRLN alert in real time by email
S-8 POS 1 d783416ds8pos.htm S-8 POS S-8 POS

As filed with the Securities and Exchange Commission on February 22, 2024

Registration Nos. 333-265634

333-259852

333-242133

333-242129

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333-265634

Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333-259852

Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333-242133

Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333-242129

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

Freeline Therapeutics Holdings plc

(Exact name of registrant as specified in its charter)

 

 

 

England and Wales   Not Applicable
(State or other jurisdiction of
incorporation or organization)
  (IRS Employer
Identification No.)

Sycamore House

Gunnels Wood Road

Stevenage, Hertfordshire SG1 2BP

United Kingdom

(Address, including zip code, of principal executive offices)

Freeline Therapeutics Holdings plc Amended and Restated 2020 Equity Incentive Plan

Freeline Therapeutics Holdings plc 2020 Equity Incentive Plan

Freeline Therapeutics Holdings plc 2020 Employee Share Purchase Plan

Freeline Therapeutics Holdings plc Amended and Restated 2021 Equity Inducement Plan

Freeline Therapeutics Holdings plc 2021 Equity Inducement Plan

Amended and Restated Freeline Therapeutics Holdings Limited Share Option Plan

(Full titles of the plans)

Freeline Therapeutics, Inc.

c/o CT Corporation

Corporation Trust Center

1209 Orange Street

Wilmington, DE 19808

(302) 636-5401

(Name and address, including zip code, and telephone number, including area code, of agent for service)

With copy to:

Matthew J. Gardella, Esq.

Matthew W. Tikonoff, Esq.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

One Financial Center

Boston, Massachusetts 02111

617 542 6000

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 

 


DEREGISTRATION OF SECURITIES

These post-effective amendments (the “Post-Effective Amendments”) are being filed by Freeline Therapeutics Holdings plc (the “Registrant”), to remove from registration all of the Registrant’s ordinary shares, par value £0.00001 (“Ordinary Shares”), which may be represented by American Depositary Shares (“ADSs”), remaining unissued and unsold under the following Registration Statements on Form S-8 (the “Registration Statements”) filed by the Registrant with the Securities and Exchange Commission (the “SEC”):

 

   

Registration Statement No. 333-265634, filed on June 15, 2022, registering (i) 10,509,486 Ordinary Shares under the Freeline Therapeutics Holdings plc Amended and Restated 2020 Equity Incentive Plan (the “2020 Plan”), (ii) 347,447 Ordinary Shares under the Freeline Therapeutics Holdings plc 2020 Employee Share Purchase Plan, and (iii) 2,000,000 Ordinary Shares under the Freeline Therapeutics Holdings plc Amended and Restated 2021 Equity Inducement Plan;

 

   

Registration Statement No. 333-259852, filed on September 28, 2021, registering 1,400,000 Ordinary Shares issuable pursuant to the Freeline Therapeutics Holdings plc 2021 Equity Inducement Plan;

 

   

Registration Statement No. 333-242133, filed on August 7, 2020, registering 2,424,156 Ordinary Shares issuable pursuant to the Amended and Restated Freeline Therapeutics Holdings Limited Share Option Plan; and

 

   

Registration Statement No. 333-242129, filed on August 7, 2020, registering (i) 3,474,469 Ordinary Shares issuable pursuant to the Freeline Therapeutics Holdings plc 2020 Equity Incentive Plan, and (ii) 347,447 issuable pursuant to the Freeline Therapeutics Holdings plc 2020 Employee Share Purchase Plan.

On November 22, 2023, the Registrant entered into an Implementation Agreement with Bidco 1354 Limited (“Bidco”), a wholly owned subsidiary of Syncona Portfolio Limited, pursuant to which Bidco agreed to acquire the entire issued and to be issued share capital of the Registrant (other than any treasury shares) not already owned by Syncona Portfolio Limited by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the “Scheme”). On February 12, 2024, the Registrant held a Court Meeting and a General Meeting at which the Registrant’s shareholders approved the Scheme and on February 19, 2024, the High Court of Justice of England and Wales sanctioned the Scheme, after which the Scheme was registered with the UK Companies House on February 20, 2024 and became effective.

As a result of the Scheme, the offerings pursuant to the Registration Statements have been terminated. In accordance with an undertaking made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities registered under the Registration Statements that remain unsold at the termination of the offerings, the Registrant hereby removes from registration all of the securities registered but unsold under the Registration Statements as of the date hereof, if any. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities.

In addition, on February 20, 2024, the Nasdaq Capital Market filed a Form 25 to delist the Registrant’s ADSs.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in New York, New York, on February 22, 2024.

 

FREELINE THERAPEUTICS HOLDINGS PLC
By:  

/s/ Michael J. Parini

Name:   Michael J. Parini
Title:   Chief Executive Officer

No other person is required to sign these Post-Effective Amendments to the Registration Statements in reliance upon Rule 478 under the Securities Act of 1933, as amended.

Get the next $FRLN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$FRLN

DatePrice TargetRatingAnalyst
2/1/2022Overweight → Equal-Weight
Morgan Stanley
1/7/2022Neutral → Buy
Redburn
11/29/2021$10.00Buy
BTIG
8/18/2021$30.00 → $20.00Buy
HC Wainwright & Co.
8/17/2021$27.00 → $8.00Overweight → Neutral
JP Morgan
8/17/2021Overweight → Neutral
JP Morgan
More analyst ratings

$FRLN
Press Releases

Fastest customizable press release news feed in the world

See more
  • Freeline to Present New Data on its Gaucher and Parkinson's Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

    Late-breaking oral presentation on results from Phase 1/2 study of FLT201 in Gaucher disease Poster presentation to highlight Freeline's GBA1 Parkinson's disease research program LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics today announced the acceptance of multiple abstracts, including one for a late-breaking oral presentation on new clinical data from its Gaucher disease program, at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place May 7-11, 2024 in Baltimore, Maryland. "Gaucher disease is a severe and progressive disorder that leads to a wide range of symptoms, including enlarged organs, bone pain and fractures, low bl

    $FRLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Acquisition of Freeline by Syncona Becomes Effective

    LONDON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) ("Freeline") and Syncona Ltd ("Syncona") today announced that, in connection with Syncona's acquisition of Freeline by way of a scheme of arrangement (the "Scheme"), the Scheme has been sanctioned by the Court and the court order (together with a copy of the scheme circular published by Freeline on January 18, 2024 (the "Scheme Circular") has been delivered to the Registrar of Companies.   Accordingly, the Scheme has become Effective in accordance with its terms and the entire issued share capital of Freeline is now owned or controlled by Syncona Portfolio Limited. Capitalized terms in this an

    $FRLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Freeline Shareholders Approve Acquisition by Syncona

    LONDON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) ("Freeline") and Syncona Ltd ("Syncona") today announced that Freeline's shareholders have approved the proposal for Bidco 1354 Limited ("Bidco"), a wholly owned subsidiary of Syncona Portfolio Limited ("Syncona Portfolio"), to acquire all shares of Freeline not currently owned by Syncona Portfolio for $6.50 per American Depositary Share ("ADS") in cash (the "Acquisition"). As previously announced, Freeline and Bidco entered into an implementation agreement on November 22, 2023 to implement the Acquisition by means of a scheme of arrangement pursuant to Part 26 of the UK Companies Act 2006 (the "Sche

    $FRLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$FRLN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$FRLN
SEC Filings

See more

$FRLN
Leadership Updates

Live Leadership Updates

See more
  • Genespire appoints Dr. Sabah Sallah as Chief Medical Officer

    Genespire appoints Dr. Sabah Sallah as Chief Medical Officer Accomplished executive with extensive preclinical and clinical gene therapy experience joins Genespire to accelerate pipeline to the clinic Milan, Italy, 7 July 2022: Genespire, a next generation gene therapy company developing first-in-class transformative therapies with advanced lentiviral vectors, today announces the appointment of Dr. Sabah Sallah MD, PhD as Chief Medical Officer. Dr. Sallah will lead the Company's clinical strategy, development and operations as Genespire progresses its novel advanced lentiviral gene therapy platforms towards the clinic. Dr. Sallah is a board-certified hematologist who has spent more than

    $FRLN
    $QURE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • Freeline Appoints Paul Schneider as Chief Financial Officer

    LONDON, April 19, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) (the "Company" or "Freeline") today announced that Paul M. Schneider has been appointed Chief Financial Officer (CFO), effective May 16, 2022, based in Boston. Mr. Schneider joins Freeline from Exo Therapeutics, Inc., where he served as Senior Vice President, Finance and Operations. A seasoned financial executive with more than 20 years of leadership experience in large and small private and public biopharmaceutical companies, Mr. Schneider brings an impressive track record of financial stewardship, including corporate strategy and execution, financial planning, analysis and reporting, and investor

    $FRLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Freeline Appoints Henning R. Stennicke, PhD, as Chief Scientific Officer to Lead Research and Discovery

    LONDON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) (the "Company" or "Freeline"), a clinical-stage biotechnology company developing transformative adeno-associated virus ("AAV") vector-mediated systemic gene therapies for people with inherited systemic debilitating diseases, today announced the expansion of its executive leadership team with the appointment of Henning R. Stennicke, PhD, as Chief Scientific Officer (CSO). Dr. Stennicke has been appointed to the role of CSO effective March 1, 2022. He will be based in Stevenage, UK, and report to Michael Parini, Freeline's Chief Executive Officer, as part of the executive leadership team. As CSO, Dr.

    $FRLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$FRLN
Financials

Live finance-specific insights

See more
  • Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease

    Robust increases of up to 700-fold over baseline in plasma GCase enzyme activity in first two patients treated with FLT201 Normalization of leukocyte GCase in both patients demonstrates cellular uptake from plasma FLT201 has been well tolerated, with no serious adverse events Company to host conference call today at 8 a.m. ET LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) today reported positive initial safety, tolerability and enzyme activity data from the ongoing Phase 1/2 GALILEO-1 trial evaluating FLT201, its adeno-associated virus (AAV) gene therapy candidate, in Gaucher disease. Gaucher disease is a debilitatin

    $FRLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Freeline Reports Second Quarter 2023 Financial Results and Business Highlights

    Completed dosing in first cohort of Phase 1/2 GALILEO-1 trial of FLT201 in Gaucher disease; expect to report initial clinical data in third quarter of 2023 Extending impact of its novel GCase variant with research program for GBA1-linked Parkinson's disease Management to host conference call at 8:00 a.m. ET today LONDON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) today reported financial results for the second quarter of 2023 and provided a business update. "FLT201 is a potential first- and best-in-class gene therapy for Gaucher disease Type 1, the most common type of the disease," said Michael Parini, Chief Exec

    $FRLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call

    LONDON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 15, 2023 to report its second quarter financial results and provide a corporate update. Participants may access this event via the teleconferencing numbers below and asking to join the Freeline call or through the webcast link here. Domestic: 1-866-524-3160International: 1-412-317-6760 While not required, it is recommended that participants join the call 10 minutes prior to the scheduled start. A live webcast of the call will also be available on the Investors section of Freeline's website at ww

    $FRLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$FRLN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more